Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8WV92
UPID:
MITD1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8WV92; Q69YV0
Background:
MIT domain-containing protein 1 plays a crucial role in cell division, specifically in the abscission phase of cytokinesis. This process is essential for the separation of daughter cells, with the protein working alongside the ESCRT-III complex to ensure efficient cell division.
Therapeutic significance:
Understanding the role of MIT domain-containing protein 1 could open doors to potential therapeutic strategies. Its pivotal function in cell division highlights its potential as a target in diseases characterized by abnormal cell proliferation.